IRIS
SCALISE, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.743
EU - Europa 2.572
AS - Asia 732
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 8.057
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.728
UA - Ucraina 779
TR - Turchia 410
IE - Irlanda 408
SE - Svezia 329
DE - Germania 322
DK - Danimarca 292
IT - Italia 195
FI - Finlandia 165
KR - Corea 155
SG - Singapore 122
GB - Regno Unito 44
IR - Iran 24
CN - Cina 16
CA - Canada 15
BE - Belgio 11
FR - Francia 7
NL - Olanda 6
RO - Romania 6
CL - Cile 5
BG - Bulgaria 4
EU - Europa 3
IN - India 3
HK - Hong Kong 2
A1 - Anonimo 1
ES - Italia 1
HR - Croazia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 8.057
Salva come PNG Salva come JPEG
Città #
Jacksonville 784
Chandler 506
Fairfield 491
Dublin 408
Wilmington 287
Ashburn 238
Woodbridge 228
Boardman 209
Houston 198
New York 185
Cambridge 168
Seattle 165
Lawrence 157
Princeton 157
San Mateo 156
Ann Arbor 140
Des Moines 82
Turin 60
San Diego 52
Izmir 23
Beijing 15
Norwalk 14
Falls Church 12
Redmond 12
Brussels 11
Helsinki 10
Kilburn 10
Ottawa 10
London 9
Centro 8
Buffalo 7
Washington 5
Amsterdam 4
Pesaro 4
Venice 4
Andover 3
Campobasso 3
Cingoli 3
Dallas 3
North Bergen 3
Palermo 3
San Jose 3
Acton 2
Arco 2
Cava De' Tirreni 2
Central 2
Hounslow 2
Marche 2
Milan 2
Olgiate Comasco 2
Serra 2
Simi Valley 2
Toronto 2
Appignano 1
Auburn Hills 1
Auckland 1
Barcelona 1
Belvedere Spinello 1
Bologna 1
Chiswick 1
Delhi 1
East Los Angeles 1
Ferrara 1
Florence 1
Fort Worth 1
Hanover 1
Hull 1
La Canada Flintridge 1
Las Vegas 1
Los Angeles 1
Macerata 1
Marseille 1
Montesilvano 1
Montréal 1
Moscow 1
Mountain View 1
Napoli 1
Nashville 1
New Delhi 1
Ozzano Monferrato 1
Perugia 1
Porto 1
Prescot 1
Pune 1
Red Deer 1
Regina 1
Riva 1
Rome 1
Silver Spring 1
Squinzano 1
St. Petersburg 1
Tehran 1
Torun 1
Zagreb 1
Totale 4.913
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 142
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. 123
Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections 108
Anticryptosporidial activity of paromomycin. 101
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock 82
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides 79
Epidemiology and microbiology of surgical wound infections. 78
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 78
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 75
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 75
In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. 74
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 74
In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 70
Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. 70
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 70
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 68
In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 67
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. 67
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock 67
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 66
RNAIII-Inhibiting Peptide-Loaded Polymethylmethacrylate Prevents In Vivo Staphylococcus aureus Biofilm Formation 66
Amphibian Peptides Prevent Endotoxemia and Bacterial Translocation in Bile Duct-Ligated Rats 66
In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. 65
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. 65
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 64
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 64
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 64
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 64
Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. 64
In- vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii. 64
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock 63
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 63
Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock 62
In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus faecalis and interactions with clinically used antibiotics. 62
In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. 62
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. 62
Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide 62
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 62
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 61
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 61
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 60
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. 60
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 60
RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 59
In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. 59
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 58
Effect of mono-dose intraperitoneal cecropins in experimental septic shock 58
Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. 58
Treatment of Staphylococcus aureus Biofilm infection by the quorum sensing inhibitor RIP 57
Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide 57
In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. 57
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 57
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 57
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 57
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 57
In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 56
Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. 56
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 56
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. 56
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 55
In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. 55
LL-37 protects rats against lethal gram-negative sepsis. 54
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. 54
Potential therapeutic role of cationic peptides in three experimental models of septic shock 53
The bovine antimicrobial peptide BMAP-28 reduces lethality due to bacterial cell wall components in mouse models of staphylococcal sepsis 53
In-Vitro Activity of Histatins Derivative P-113 Alone and in Combination with Antimicrobial Agents Against Multidrug-Resistant Pathogens Responsible of Pneumonia in Immunocompromised Patients. 53
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 53
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 52
In vitro activities of tachyplesin III against Pseudomonas aeruginosa. 51
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 51
Polycationic peptides as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection 51
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. 51
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. 50
In Vitro Activity of Aurein 1.2 Alone and in Combination with Antibiotics against Gram-positive Nosocomial Cocci 50
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 50
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to multiresistant Pseudomonas aeruginosa strain 49
Potential therapeutic role of histatins derivative P-113D in experimental rat models of Pseudomonas sepsis 49
Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. 49
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. 49
Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. 49
RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. 49
The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock 49
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock 49
Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. 48
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. 48
Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa. 48
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. 48
In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 48
In-vitro effect of short-term exposure to cathelicidin peptides on Cryptosporidium parvum. 47
Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? 47
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 47
In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. 47
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. 47
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 46
[Vascular graft infection by Staphylococcus epidermidis: efficacy of various perioperative prophylaxis protocols in an animal model]. 46
Therapeutic efficacy of the magainin analog MSI-78 in different intra-abdominal sepsis rat models 45
Efficacy of Tachyplesin III, Colistin and Imipenem against Multiresistant Pseudomonas aeruginosa 45
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. 45
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species 45
RNA III Inhibiting Peptide (RIP) inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus 44
Totale 6.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.512
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.512
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201926 0 0 0 0 0 0 0 0 0 1 0 25
2019/2020920 2 0 158 2 156 3 167 3 160 18 19 232
2020/20212.164 115 250 325 42 242 159 216 147 207 166 195 100
2021/20221.154 88 240 0 51 9 106 45 63 73 194 37 248
2022/20231.684 202 170 135 121 124 180 4 82 487 8 128 43
2023/2024892 212 18 44 190 200 201 15 7 5 0 0 0
Totale 8.212